App-Quantinova.ai

IL22 expression in intestinal immune cells is not augmented by AHR activation in health or Crohn’s disease

P Harrow - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Comparison of abdominal lymph nodes between healthy volunteers and patients with Crohn’s disease

H Williams - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Gut microbiome diversity in acute severe colitis is distinct from mild-to-moderate ulcerative colitis

S Kedia - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Multi-omic data integration assisted identification of molecular features contributing to disease heterogeneity in Crohn's disease

P Sudhakar - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Tamsulosin Hydrochloride

A global prospective observational study in children and adolescents with paediatric-onset IBD: the PIBD-SETQuality inception cohort

M A Aardoom - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

System delays have real consequences: Impact of timing of biologic commencement on inflammatory bowel disease patient response

A McCulloch - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Endoscopic healing assessed by advanced optical enhancement techniques combined with faecal calprotectin (FCP) can accurately assess histological healing in ulcerative colitis patients

R Cannatelli - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

ABT-494

The clinical utility of low radiation dose computed tomography as a first-line investigation for evaluation of small bowel pathology

A Patel - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Microscopic colitis: a missed opportunity to diagnose during colonoscopy

S A Raju - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

ABT-494

A novel ileocolonic Crohn’s staging tool: the development and validation of an evidence-based, end-user informed radiological decision-aid

P S Morar - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Can patients enter the ‘Standard Set’ ICHOM parameters by completing electronic questionnaires?

A Walsh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Purely fibrostenotic Crohn’s disease without chronic inflammation is uncommon – a histopathologic study of resected intestine

U N Shivaji - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Oesophageal Crohn’s disease: diagnosis and outcome of an ECCO-CONFER case series

R Rodrigues - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Crohn's disease

N/A

Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry

E Louis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort

L Peyrin-Biroulet - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Etrolizumab

Prediction model to safely cease anti-TNF therapy in Crohn’s disease: individual patient data meta-analysis (IPD-MA)

R W M Pauwels - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Understanding patient perspectives on dysplasia cancer risk and its management

M Kabir - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Challenges in colonoscopic surveillance in chronic IBD

S-L Gillespie - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

45280 Abstracts